DB-OTO / Regeneron - LARVOL DELTA

The CHORD trial: an update on the efficacy and safety of DB-OTO gene therapy for profound deafness in children (ASGCT 2026) - No abstract available

Clinical • Gene therapy • Gene Therapies • Otorhinolaryngology

Safety and Efficacy of DB-OTO Gene Therapy in Children With Profound Deafness Due to Otoferlin Variants: Data From the Chord First-In-Human Registrational Trial (ARO 2026) - P1/2 | "In this first-in-human registrational gene therapy trial, DB-OTO resulted in significant hearing improvements in participants with OTOF-related deafness. DB-OTO administration enabled natural acoustic hearing for the first time, and normalized hearing sensitivity in some participants."

Clinical • First-in-human • Gene therapy • P1 data • Gene Therapies • Otorhinolaryngology